#amgen
amgen
422 views
8 Discussing
Hot
Latest
·
--
Why did Amgen stock fall during a 41% year? Three episodes explain the dips.First, MariTide Phase 2 showed 20% weight loss, but analysts expected 25%. The shortfall triggered selling. Deutsche Bank called results underwhelming and kept a $305 target. Second, Prolia and XGEVA dropped 33% in Q2 as biosimilar competition arrived faster than modeled. Third, management warned operating expenses would rise in the second half.
All three sell-offs had one thing in common: the core business was intact. Revenue grew 10% in Q2 to over $10 billion. Guidance was raised. Growth products outpaced legacy declines.
Expectation misses are different from execution failures. Amgen stock's dips were the first kind. My approach is to evaluate each dip against the revenue trajectory. Your process may differ.
#AMGN #Amgen #StockAnalysis #Pharma #Pipeline
Why did Amgen stock fall during a 41% year? Three episodes explain the dips.
First, MariTide Phase 2 showed 20% weight loss, but analysts expected 25%. The shortfall triggered selling. Deutsche Bank called results underwhelming and kept a $305 target. Second, Prolia and XGEVA dropped 33% in Q2 as biosimilar competition arrived faster than modeled. Third, management warned operating expenses would rise in the second half.
All three sell-offs had one thing in common: the core business was intact. Revenue grew 10% in Q2 to over $10 billion. Guidance was raised. Growth products outpaced legacy declines.
Expectation misses are different from execution failures. Amgen stock's dips were the first kind. My approach is to evaluate each dip against the revenue trajectory. Your process may differ.
#AMGN #Amgen #StockAnalysis #Pharma #Pipeline
All three sell-offs had one thing in common: the core business was intact. Revenue grew 10% in Q2 to over $10 billion. Guidance was raised. Growth products outpaced legacy declines.
Expectation misses are different from execution failures. Amgen stock's dips were the first kind. My approach is to evaluate each dip against the revenue trajectory. Your process may differ.
#AMGN #Amgen #StockAnalysis #Pharma #Pipeline
1
151
What is the price target for Amgen stock? The consensus sits near $358 from 36 analysts, with a range of $305 (Deutsche Bank) to $450 (Street high). At $402, the stock trades above the April average but within the range of post-Q2 upgrades.
Key context: 18 of 36 analysts rate Amgen Hold, not Buy. That means the consensus is mixed. The wide target spread signals disagreement on MariTide's pipeline value and the pace of Prolia biosimilar erosion.
Q3 earnings will likely determine whether targets move up to meet the price or the price corrects down to meet the targets. Just my read on how to interpret the spread.
#AMGN #Amgen #PriceTarget #StockAnalysis #Pharma
What is the price target for Amgen stock? The consensus sits near $358 from 36 analysts, with a range of $305 (Deutsche Bank) to $450 (Street high). At $402, the stock trades above the April average but within the range of post-Q2 upgrades.
Key context: 18 of 36 analysts rate Amgen Hold, not Buy. That means the consensus is mixed. The wide target spread signals disagreement on MariTide's pipeline value and the pace of Prolia biosimilar erosion.
Q3 earnings will likely determine whether targets move up to meet the price or the price corrects down to meet the targets. Just my read on how to interpret the spread.
#AMGN #Amgen #PriceTarget #StockAnalysis #Pharma
Key context: 18 of 36 analysts rate Amgen Hold, not Buy. That means the consensus is mixed. The wide target spread signals disagreement on MariTide's pipeline value and the pace of Prolia biosimilar erosion.
Q3 earnings will likely determine whether targets move up to meet the price or the price corrects down to meet the targets. Just my read on how to interpret the spread.
#AMGN #Amgen #PriceTarget #StockAnalysis #Pharma
1
118
·
--
Amgen stock near $402 before Q3 2026 earnings. The setup: revenue crossed $10B in Q2, guidance raised to $38.2B to $39.4B, and the stock rallied 41% year to date. But management warned operating expenses would rise in the second half.
The risk is margin compression. Q2 non-GAAP margin hit 48%. If Q3 expenses climb as warned while revenue meets rather than beats consensus, margins could dip to the low 40s. For a stock at 25x trailing earnings, that compression matters.
Watching for: revenue above $9.5B, margin above 44%, and Prolia trajectory. Biosimilar pressure took Prolia and XGEVA down 33% in Q2. Not adding before earnings. Your approach may differ.
#AMGN #Amgen #Earnings #Pharma #BioTech
Amgen stock near $402 before Q3 2026 earnings. The setup: revenue crossed $10B in Q2, guidance raised to $38.2B to $39.4B, and the stock rallied 41% year to date. But management warned operating expenses would rise in the second half.
The risk is margin compression. Q2 non-GAAP margin hit 48%. If Q3 expenses climb as warned while revenue meets rather than beats consensus, margins could dip to the low 40s. For a stock at 25x trailing earnings, that compression matters.
Watching for: revenue above $9.5B, margin above 44%, and Prolia trajectory. Biosimilar pressure took Prolia and XGEVA down 33% in Q2. Not adding before earnings. Your approach may differ.
#AMGN #Amgen #Earnings #Pharma #BioTech
The risk is margin compression. Q2 non-GAAP margin hit 48%. If Q3 expenses climb as warned while revenue meets rather than beats consensus, margins could dip to the low 40s. For a stock at 25x trailing earnings, that compression matters.
Watching for: revenue above $9.5B, margin above 44%, and Prolia trajectory. Biosimilar pressure took Prolia and XGEVA down 33% in Q2. Not adding before earnings. Your approach may differ.
#AMGN #Amgen #Earnings #Pharma #BioTech
67
·
--
What is the Amgen dividend for the first quarter of 2026? Amgen declared a quarterly dividend of $2.52 per share, up 6% from the prior year. At a stock price near $402, that translates to a 2.50% annualized yield.
The payout is well covered by free cash flow of $3.5 billion in Q2 2026. Total annual dividend cost is approximately $5.4 billion across 540 million shares. With non-GAAP EPS guidance of $22.30 to $23.50, the payout ratio sits around 43% to 45%, leaving room for continued growth.
Amgen has increased dividends annually for over a decade. The $57.3 billion in debt is a consideration, but current cash flow supports both debt service and dividends. Not financial advice.
#AMGN #Amgen #Dividend #IncomeInvesting #Pharma
What is the Amgen dividend for the first quarter of 2026? Amgen declared a quarterly dividend of $2.52 per share, up 6% from the prior year. At a stock price near $402, that translates to a 2.50% annualized yield.
The payout is well covered by free cash flow of $3.5 billion in Q2 2026. Total annual dividend cost is approximately $5.4 billion across 540 million shares. With non-GAAP EPS guidance of $22.30 to $23.50, the payout ratio sits around 43% to 45%, leaving room for continued growth.
Amgen has increased dividends annually for over a decade. The $57.3 billion in debt is a consideration, but current cash flow supports both debt service and dividends. Not financial advice.
#AMGN #Amgen #Dividend #IncomeInvesting #Pharma
The payout is well covered by free cash flow of $3.5 billion in Q2 2026. Total annual dividend cost is approximately $5.4 billion across 540 million shares. With non-GAAP EPS guidance of $22.30 to $23.50, the payout ratio sits around 43% to 45%, leaving room for continued growth.
Amgen has increased dividends annually for over a decade. The $57.3 billion in debt is a consideration, but current cash flow supports both debt service and dividends. Not financial advice.
#AMGN #Amgen #Dividend #IncomeInvesting #Pharma
71
🚨 AMGNUSDT Latest News – November 1, 2026
📢 Binance Adds AMGNUSDT Perpetual Contract!
Binance has introduced AMGNUSDT, a new TradFi futures contract linked to Amgen Inc., a major biotechnology and pharmaceutical company.
🔹 New Listing: AMGNUSDT launched on Binance Futures on October 29, 2026.
🔹 Underlying Asset: Amgen Inc. (AMGN) stock.
🔹 Settlement: USDT.
🔹 Trading Hours: 24/7.
🔹 Latest Market Snapshot: AMGN was reported near 469.17 USDT, with a 24-hour change of approximately -0.30% in the latest available data.
📊 Market Update: This contract connects traditional stock-market exposure with crypto exchange futures infrastructure.
⚠️ AMGNUSDT is a futures contract, not an actual cryptocurrency or ownership of Amgen shares. Futures involve substantial risk. This post is for information only.
#AMGNUSDT #Amgen #Binance #TradFi #CryptoNews #StockMarket #USDT
🚨 AMGNUSDT Latest News – November 1, 2026
📢 Binance Adds AMGNUSDT Perpetual Contract!
Binance has introduced AMGNUSDT, a new TradFi futures contract linked to Amgen Inc., a major biotechnology and pharmaceutical company.
🔹 New Listing: AMGNUSDT launched on Binance Futures on October 29, 2026.
🔹 Underlying Asset: Amgen Inc. (AMGN) stock.
🔹 Settlement: USDT.
🔹 Trading Hours: 24/7.
🔹 Latest Market Snapshot: AMGN was reported near 469.17 USDT, with a 24-hour change of approximately -0.30% in the latest available data.
📊 Market Update: This contract connects traditional stock-market exposure with crypto exchange futures infrastructure.
⚠️ AMGNUSDT is a futures contract, not an actual cryptocurrency or ownership of Amgen shares. Futures involve substantial risk. This post is for information only.
#AMGNUSDT #Amgen #Binance #TradFi #CryptoNews #StockMarket #USDT
📢 Binance Adds AMGNUSDT Perpetual Contract!
Binance has introduced AMGNUSDT, a new TradFi futures contract linked to Amgen Inc., a major biotechnology and pharmaceutical company.
🔹 New Listing: AMGNUSDT launched on Binance Futures on October 29, 2026.
🔹 Underlying Asset: Amgen Inc. (AMGN) stock.
🔹 Settlement: USDT.
🔹 Trading Hours: 24/7.
🔹 Latest Market Snapshot: AMGN was reported near 469.17 USDT, with a 24-hour change of approximately -0.30% in the latest available data.
📊 Market Update: This contract connects traditional stock-market exposure with crypto exchange futures infrastructure.
⚠️ AMGNUSDT is a futures contract, not an actual cryptocurrency or ownership of Amgen shares. Futures involve substantial risk. This post is for information only.
#AMGNUSDT #Amgen #Binance #TradFi #CryptoNews #StockMarket #USDT
55
$MELI USDT is down 1.06% at $1,647.38, while PFEUSDT is gaining 0.88% at $29.96. $AMGN USDT is up 0.46% at $470.17, and $OXY USDT is slightly down 0.24% at $63.65. Meanwhile, SMRUSDT is leading the gainers with a 1.13% increase at $5.724
#CryptoMarket #TradingUpdate #PerpetualTrading #Amgen #MarketAnalysis
$MELI USDT is down 1.06% at $1,647.38, while PFEUSDT is gaining 0.88% at $29.96. $AMGN USDT is up 0.46% at $470.17, and $OXY USDT is slightly down 0.24% at $63.65. Meanwhile, SMRUSDT is leading the gainers with a 1.13% increase at $5.724
#CryptoMarket #TradingUpdate #PerpetualTrading #Amgen #MarketAnalysis
#CryptoMarket #TradingUpdate #PerpetualTrading #Amgen #MarketAnalysis
1
677
Log in to explore more content
Join global crypto users on Binance Square
⚡️ Get latest and useful information about crypto.
💬 Trusted by the world’s largest crypto exchange.
👍 Discover real insights from verified creators.
Email / Phone number
Trending Topics
1
#NvidiaInvestigatesAfterHuang’sAffairApology
115,863 views
1,240 Discussing
2
#BitcoinFiveWeeklyLosses
142,339 views
1,704 Discussing
3
#AIChipSlumpNasdaq
73,644 views
1,064 Discussing
4
#CPITestsDecemberRateOutlook
569,841 views
2,503 Discussing
5
#AnthropicRejectsIPODelayValuationinQuestion
14,356 views
277 Discussing
6
#CryptoLiquidationsReach$1.16BIn24Hours
1,677 views
22 Discussing
7
#BrentCrudeDrops3.8%To$94.56
1,589 views
15 Discussing
8
#EUInstitutionsInviteIndustryToSetTokenizedSecuritiesStandards
786 views
8 Discussing
9
#ChinaCACListsFiveIssuesAffectingBlockchainFilings
4,575 views
83 Discussing
10
#UKBanksCanNowApplyToConductCryptoAssetBusiness
3,384 views
63 Discussing